scispace - formally typeset
J

Johannes H. T. M. Koelman

Researcher at University of Amsterdam

Publications -  134
Citations -  5619

Johannes H. T. M. Koelman is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Dystonia & Myoclonus. The author has an hindex of 40, co-authored 129 publications receiving 5154 citations.

Papers
More filters
Journal ArticleDOI

Prediction of poor outcome within the first 3 days of postanoxic coma

TL;DR: Poor outcome in postanoxic coma can be reliably predicted with somatosensory evoked potentials and neuron-specific enolase as early as 24 hours after cardiopulmonary resuscitation in a substantial number of patients.
Journal ArticleDOI

Systematic review of early prediction of poor outcome in anoxic-ischaemic coma.

TL;DR: Because evoked potentials are also the least susceptible to metabolic changes and drugs, recording of SSEP is the most useful method to predict poor outcome.
Journal ArticleDOI

Prognosis of coma after therapeutic hypothermia: a prospective cohort study.

TL;DR: This study was designed to establish the reliability of neurologic examination, neuron‐specific enolase (NSE), and median nerve somatosensory‐evoked potentials (SEPs) to predict poor outcome in patients treated with mild hypothermia after cardiopulmonary resuscitation (CPR).
Journal ArticleDOI

A meta-analysis of P50 studies in patients with schizophrenia and relatives: Differences in methodology between research groups

TL;DR: Whether patients with schizophrenia as well as their relatives show deficits in sensory gating reflected by an abnormal P50 ratio and to quantify the differences from controls is determined and P50 suppression would not qualify as an endophenotype for schizophrenia.
Journal ArticleDOI

Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo’s oil”

TL;DR: It is advocated that “Lorenzo’s oil” should not be prescribed routinely to patients with X-ALD who already have neurological deficits, and side effects were often noted—namely, mild increases in liver enzymes, thrombocytopenia, gastrointestinal complaints, and gingivitis.